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Objectives: To search for more effective radiation protectors with minimal toxicity, a water-soluble nitroxides
Acetamido-Tempol (AA-Tempol) was evaluated for potential radioprotective properties in HUVEC cells (Human
Umbilical Vein Endothelial cell line).
Methods: To study the anti-radiation effect of AA-Tempol in cell culture, the viability of irradiated HUVEC
cells using a clonogenic survival assay was examined. The anti-apoptosis effects of AA-Tempol using Annexin
V/propidium iodide staining in a flow cytometry assay was also evaluated. To elucidate the molecular mechanism of
the anti-apoptosis effect of AA-Tempol against X-radiation induced HUVEC cell apoptosis, the expression of Bax, Bcl-2
and p53 and caspase-3 were examined. The changes in the level of malondialdehyde (MDA) and glutathione (GSH) in
HUVEC cells after X-radiation were also investigated.
Results: Pretreatment of the HUVEC cells colony with AA-Tempol 1 h before X-radiation significantly increased the
colony survival (p < 0.05) compared with the cells without pretreatment. This demonstrates that AA-Tempol provides
an effective radiation protection in the irradiated HUVEC cells, thus reducing apoptosis from 20.1 ± 1.3% in 8 Gy
X-radiated cells to 12.2 ± 0.9% (1.0 mmol/L−1 AA-Tempol) in AA-Tempo pretreated HUVEC cells. This implies that 1.
0 mM AA-Tempol treatment significantly block the increase of caspase-3 activity in radiated HUVEC cells (P < 0.01),
causing down-regulation in expressions of Bax and P53 and up-regulation in the expression of Bcl-2. Pretreatment with
AA-Tempol also decreased the MDA activities (P < 0.01) and increase the GSH level (P < 0.05) in HUVEC cells compared
to the 8Gy X-radiated cells without pretreatment.
Conclusions: These observations indicate that AA-Tempol is a potential therapeutic agent against the radiation damage.
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With the advent of new technologies, ionizing radiation
(X- and gamma-rays) has been widely used in different
fields during the last decades, both in every branch of
medicine, to diagnostic and diseases treatment; and in
several industries,where human exposure to ionizing
radiation has increased tremendously [1, 2]. Ionizing* Correspondence: dingzhao@fmmu.edu.cn; whb7691@163.com
†Equal contributors
1School of Preventive Medicine, Fourth Military Medical University, Xi’an
710032, People’s Republic of China
2School of Pharmacy, Fourth Military Medical University, Xi’an 710032,
People’s Republic of China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeradiation causes damage to living tissues through a series
of molecular events depending on the radiation energy.
Its damaging effects and the intensity on human health
have been reported [3]. Due to the hazardous effects of
the ionizing radiation, the ability of some chemical com-
pounds to protect cells from damaging effects of ioniz-
ing radiation has been reported. For instance, Patt et al.
[4] made initial discovery about the protective effects of
cysteine on the X-irradiation damage in mice. Other
new agents, such as amifostine (WR2721) has been
discovered and clinically approved by the Food and Drug
Administration for reducing the side effects ofle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 The chemical structure of AA-Tempol
Wang et al. Environmental Health and Preventive Medicine  (2017) 22:14 Page 2 of 10radiotherapy in patients [5]. Several studies have also
demonstrated that amifostine protects normal tissue
from both acute and late radiation damage without
protecting the tumor. In another term amifostine is a
selective cytoprotector of normal tissues [6–9]. However,
WR2721 has some side-effects such as hypotension,
nausea, and vomiting, which are significantly augmented
upon intravenous administration [10–12]. Hence, the
development of effective and less toxic radioprotection
agents is of great importance [13].
The biological effects of ionizing radiation are linked
to the production of reactive oxygen species (ROS) in
organisms which interact with critical macromolecules,
such as DNA, proteins or membranes and lead to muta-
tions and chromosomal aberrations [14]. The DNA
damage is one of the most important side effects of ion-
izing radiation [15]. The ROS mediated bimolecular re-
actions and their relationship with radiation side effects
are the current subject of scientific investigations in
radiotherapy. To address this problem, some chemical
agents have been investigated as scavengers of ROS,
thus serve as effective radioprotectors againstzradia-
tion damage [16]. Another benefit is their supplemen-
tation of antioxidants to improve the efficacy of
radiotherapy. A wide range of phytochemicals that
have been investigated for this purpose include, flavo-
noids, polyphenols, carotenoids, and organosulfur
compounds [17].
In recent years, nitronyl nitroxide radicals have been
extensively studied due to their antioxidative properties
to protect against oxidative damage [18–20]. Nitronyl
nitroxide radicals can directly react with ROS [21] to
prevent the reduction of hydrogen peroxide to the hy-
droxyl radical [22], which occured through the redox
transformations between the oxidation states of nitrox-
ide, hydroxylamine, and the oxoammonium cation. The
nitroxide and oxoammonium cation paired the redox
couple. The redox couple which paired by nitroxide and
oxoammonium cation can support catalytic processes
via reversible one-electron redox reactions. The
hydroxylamine can function as an efficient hydrogen
atom donor and provide antioxidant defense [23]. Tempol
(4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl) repre-
sents this new family of nitroxides that act as an effective
antioxidant in scavenging superoxide anions which has
been shown to have protective effects against ionizing
radiation [24, 25]. Tempol has been shown to protects
mammalian cells against radiation-induced cytotoxicity
in vitro [26] and can afford protection in vivo against
whole- body irradiation [27]. It was reported that a
mitochondria-targeted nitroxide/hemigramicidin S conju-
gate (TPEY-Tempol) protected mouse embryonic cells
against gamma irradiation significantly [28, 29]. To search
for more effective radiation protectors with minimaltoxicity, a water-soluble nitroxides Acetamido-Tempol
(AA-Tempol, Fig. 1) was evaluated for potential radio-
protective properties using HUVEC cells and clono-
genic assays. Its radioprotective effects in vitro were
evaluated in this study. The results showed that AA-
Tempol increased the level of GSH and decreasing
the level of MDA which acted as antioxidants by
scanvenging ROS. The present data also showed that
pretreatment with AA-Tempol can attenuated X-
radition induced cell apoptosis by regulating the
expression levels of Bcl-2, Bax, caspase-3 and P53.
These observations indicate that AA-Tempol may be
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The Human Umbilical Vein Endothelial cell line
(HUVEC) was provided by the Department of Preventive
Medicine, the Fourth Military Medical University (No.
169, Changle West Road, Xi’an, Shaanxi 710032, PR
China). They were grown at 37 °C in a humidity of 5%
CO2 in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 10000 units/
mL penicillin and 50 μg/mL streptomycin.
Cytotoxicity assay
The cytotoxicity assays was performed by the Cell
Counting Kit-8 (CCK-8) method [30]. HUVEC cells were
seeded into 96-well plates at a density of 2 × 104 cells
per well and incubated at 37 °C in a humidified atmos-
phere with 5% CO2 for 24 h. The medium was removed
and fresh DMEM containing the appropriate dilution of
the AA-Tempol was added. AA-Tempol were dissolved
in 0.01 mol/L Phosphate Buffered Saline(PBS, pH 7.4) at
32 mmol/L. HUVEC cells were seeded into 3 96-well
plates at a density of 2 × 104 cells per well and incubated
at 37 °C in a humidified atmosphere with 5% CO2 for
24 h. Then the medium was removed, the AA-Tempol
solution and fresh DMEM were added at a final AA-
Tempol concentration of 0, 0.0625, 0.25, 1, 2, 4, 8,
16 mmol/L respectively. Each concentration has 5 dupli-
cate wells in one plates. After treatment for 0.5, 1 and
2 h respectively, HUVEC cells in the plates were cul-
tured for another 48 h in fresh DMEM, then treated
with Cell Counting Kit-8 reagent (10 μL/ well) for 2 h at
37 °C. The absorbance was read at 450 nm. The experi-
ments were performed at least three times.
colony survival assay
Colony survival assay was performed using Giemsa
staining method as previously described [31]. Cells
were seeded onto 6-well plates and allowed to grow
for 24 h prior to treatment with different concentra-
tions of the AA-Tempol. AA-Tempol was solubilised
with 0.01 mol/L PBS and diluted in culture media to
achieve concentrations of 0, 1 and 2 mM. Control
cells were prepared in a similar way except that the
cell was not pretreated with AA-Tempol before irradi-
ation. Irradiation (4 and 6 Gy) was performed with a
X-ray machine at dose rate of 4.404Gy/min. The ser-
ial dilution of AA-Tempol with DMEM media in cul-
tured plates yielded final concentrations of 0, 1, 2 mM.
The different concentrations of AA Tempol was added
onto the cells at 1 h before X-ray irradiation
(0Gy,4Gy,6Gy). After 10 to 14 days incubation in fresh
DMEM in a humidified atmosphere containing 5% CO2,
the plates were fixed with 70% MeOH and stained with
0.8% Swiss Giemsa. And colonies which come from an
original surviving cell of 50 or more cells were counted assurvivors. The surviving fractions were calculated as the
plating efficiency of samples relative to that of sham-
irradiated control. The survival fractions were calculated
as (number of colonies/number of cells plated)/(number
of colonies for corresponding sham-irradiated control/
number of cells plated) [32]. The experiment was
performed at least six times.
Hoechst staining
Cell death was determined by Hoechst 33258 (Sigma)
fluorescent staining. Cell suspensions were seeded into
24-well plates at a concentration of 2 × 104 cells per well.
Cells were allowed to attach for 24 h; and then
treated with 2 mM AA-Tempol for 1 h before x-
radiation (0 and 8 Gy). The cells were washed with
PBS for three times at 0.5 h after X-ray irradiation
and then incubated for 48 h with DMEM. Then the
cells were stained with Hoechst 33258 (10 μg/ml) for
15 min, and then fixed by 4% paraformaldehyde for
10 min. Cells were observed under a fluorescence
microscope (Olympus BX61, Japan). The Hoechst dye
were excited at 340 nm. For each well, three visual
fields were selected randomly.
Flow cytometric (FCM) analysis of the cell apoptosis
Apoptosis analyses were performed as described previ-
ously [33]. Briefly, apoptosis and cell viability were mea-
sured by using annexin V-FITC (Assay Designs, Inc.
USA) and PI double staining. HUVEC cells were seeded
into 10 cm plates at a density of 5 × 105 cells per well
and allowed to grow for 24 h prior to treatment with
AA-Tempol. Then AA-Tempol was added to cultured
cells maintaining the final concentration of 1.0 mmol⋅L
−1 for 1 h before 8 Gy X-radiation. At 0.5 h after radi-
ation, the medium was removed and fresh DMEM was
added onto HUVEC cells. The untreated cells (blank
control) as well as the treated cells were incubated for
4 days. Then cells were harvested and washed twice with
0.01 mol/L PBS. Before they were measured by flow cyt-
ometer, ethanol was washed off with PBS. The cells were
diluted in 100 μl of 1× annexin-binding buffer per assay
and incubated with annexin V-FITC and PI for 15 min
at room temperature in the dark. Having been washed
with PBS, they were measured by Epics XL-4 flow
cytometer (BECKMAN-Coulter, USA) using Cellquest
software (version2) to obtain the information on
apoptosis.
Western blot analysis
Western blot analysis was performed as described previ-
ously [34]. Cultured cells were preincubated with the
concentrations of AA-Tempol (1.0 mmol⋅L−1) at 37 °C
for 1 h, then cells were exposed to 8 Gy X-radiation and
cultured for 48 h in fresh DMEM. Protein concentrations
Wang et al. Environmental Health and Preventive Medicine  (2017) 22:14 Page 4 of 10were determined by using the BCA assay kit. Proteins of
total extracts were separated on 10% SDS gels. Separated
proteins were transferred electrophoretically onto polyvi-
nylidene difluoride membrane (PVDF) (Amersham Inter-
national) and blocked with 5% non-fat milk in phosphate
buffered saline (PBS)-Tween for 2 h. The primary anti-
bodies polyclonal rabbit anti-Bcl-2 (dilution ratio 1:2000),
anti-p53 (dilution ratio 1:2000), anti- caspase3 (dilution
ratio 1:3000), GAPDH (1:5000) and with β-actin (dilution
ratio 1:3000) were incubated with the membranes at
4 °C overnight. The membranes were incubated with
a secondary antibody conjugated to horseradish-
peroxidase (Beyotime) after being washed with TBST
three times for 10 min each time, and bands were visualized
using an ECL system (Perkin Elmer). Semi-quantitation of
scanned films was performed using Quantity One-4.6.2
(Bio-Rad, Italy). The relative expression levels of the
targeted proteins were determined using beta-actin as a
loading control. All western blots were independently
replicated three times.
Biochemical assays
Cultured cells were pretreated with varied concentra-
tions of AA-Tempol (0, 0.25, 1, 4 mmol⋅L−1) at 37 °C for
1 h before 8 Gy X-radiation and cultured for another
48 h in fresh DMEM, then cells were harvested and
suspended in 0.2 ml PBS containing 0.1 ml RIPA lysis
buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS, sodium orthovana-
date, sodium fluoride, EDTA, leupeptin, 1 mM PMSF)
and intermittently vortexed for 10 min (4 °C) and centri-
fuged at 12,000 × rpm for 10 min (4 °C). The super-
natant was taken for biochemical estimations. The level
of lipid peroxidation (MDA) was assayed by analyzing
TBA-reactive substances which were determined by aFig. 2 The cytotoxicity of different concentrations (0, 0.0625, 0.25, 1, 2, 4, 8
HUVEC cells was examined by CCK-8 assay. The cells treated with 0.0625, 0
growth inhibition. The cells treated with 8 and 16 mmol⋅L−1 AA-Tempol expo
for 2 h displayed mild cell growth inhibition. *P < 0.05 vs. normal control groumethod utilizing the lipid peroxidation assay kit. The
pink-colored chromogen formed by the reaction of TBA
with breakdown products of lipid peroxidation was mea-
sured [35]. The contents of reduced glutathione (GSH)
were assayed by the commercially available cellular GSH
assay kit. In each group, six samples (n = 6) were proc-
essed. The cell protein was determined by the Lowry
method using BSA as standard. The experiment was
performed at least six times.
Statistical analysis
The statistical analysis of the data to determine signifi-
cant variations between the groups was performed using
SPSS statistical software. The one-way analysis of vari-
ance (ANOVA) test was performed, and post hoc
multiple comparisons were performed using the least
significant difference (LSD) test. The results are pre-
sented as the means ± standard deviation (SD). In all
cases, P < 0.05 was considered to indicate a statistically
significant difference.
Results
Cytotoxicity and clonogenic protection of AA-Tempol
The cytotoxicity of AA-Tempol on HUVEC cells was
examined using the CCK-8 assay. As shown in Fig. 2,
AA-Tempol did not inhibit cell growth under the
concentration of 4 mM when exposed for 0.5 h and
1 h. But when treated with the concentration of 8
and 16 mM AA-Tempol for 0.5 and 1 h, the optical
density (OD) value of HUVEC cells decreased dra-
matically which indicated that the higher concentra-
tions of AA-Tempol inhibited the cell growth greater
than those with lower concentration (P < 0.05). When
exposure for 2 h in 2, 4, 8 and 16 mmol/L AA-
Tempol, the HUVEC cells growth were significantlyand 16 mmol⋅L−1) of AA-Tempol exposure for 0.5, 1, and 2 h on
.25, 1, 2, 4 mmol⋅L−1 AA-Tempol for 0.5 and 1 h did not displayed cell
sure for 0.5 and 1 h and 2, 4, 8 and 16 mmol⋅L−1 AA-Tempol exposure
p
Fig. 3 The radioprotective effect of AA-Tempol on the viability of irradiated HUVEC cells was examined using clonogenic survival assay. Pretreatment
of different concentrations (0, 1 and 2 mmol⋅L−1) of AA-Tempol 1 h prior to X-radiation provided significant protection compared to cells treated with
radiation alone (P < 0.05)
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fects of being exposed for 1 h in 0.25, 1, 2, 4 mmol/
L AA-Tempol were investigate on HUVEC cells.
To study the anti-radiation effect of AA-Tempol in
cell culture, we examined the viability of irradiated
HUVEC cells using a clonogenic survival assay. As
shown in Fig. 3, pretreatment with AA-Tempol 1 h
before X-radiation increased the colony survival (P <
0.05) significantly compared with the cells treated
with radiation alone. The maximum protection was
achieved at 2.0 mmol⋅L−1 AA-Tempol with radiation
at 4 Gy (P < 0.05).
Protective effects against apoptosis of AA-Tempol
We evaluated the anti-apoptosis effects of AA-Tempol
on HUVEC cells using Annexin V/propidium iodide
staining in a flow cytometry assay. The results
showed that X-Ray radiation dramatically increased
the number of apoptotic cells compared with the nor-
mal control group. Pretreatment of HUVEc cells withFig. 4 Hoechst 33258 and PI staining in cultured HUVEC cells. Representati
Normal group, 8Gy X-radiation treated group, 8Gy X-radiation + 2 mmol⋅L−AA-Tempol pretreatment significantly reduced the
radiation-induced apoptosis in HUVEC cells com-
pared to the 8Gy X-radiated cells (P < 0.01) (Figs. 4
and 5). This implies that AA-Tempol demonstrated a
protective effect in irradiated HUVEC cells, thus
reducing apoptosis from 20.1 ± 1.3% in 8 Gy X-
radiated cells in untreated or control cells to 12.2 ±
0.9% in cells treated with 1 mM AA-Tempol). This
suggests that the radioprotective effect of AA-Tempol
in HUVEC cells was due to the attenuation of
radiation-induced apoptosis.
AA-Tempol upregulated Bcl-2 expression and
downregulated P53, Bax and caspase-3 expression
To elucidate the molecular mechanism of the anti-
apoptosis effect of AA-Tempol against X-radiation
induced HUVEC cell apoptosis, the expression of
Bax, Bcl-2 and p53 and caspase-3 were examined as
shown in Fig. 6. The results showed that X-radiation
induced a sharp increase in P53, Bax and the activeve fluorescence images obtained after Hoechst 33258 staining in
1 AA-Tempol treated group
Fig. 5 The anti-apoptosis effect of different concentrations (0, 0.25, 1, 4 mmol⋅L−1) of AA-Tempol pretreatment for 1 h was analyzed using
Annexin V/propidium iodide staining in a flow cytometry assay. a AA-Tempol pretreatment attenuated radiation-induced apoptosis in HUVEC cells.
b The bar graph of apoptotic cells expressed as a percentage of total cells for each treatment with SAA from six experiments. Data are presented as
mean ± S.D. (n = 6). ** P < 0.01 vs. 8 Gy group. Q1, Q2, Q3 and Q4 represent dead, late apoptosis, vital and early apoptosis cells, respectively
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crease in Bcl-2 expression. Compared with the con-
trol group, AA-Tempol treatment can significantly
block the increase of caspase-3 activity in radiated
HUVEC cells (P < 0.01). The expressions of Bax and
P53 were also down-regulated and the expression ofBcl-2 was up-regulated in the 1.0 mM AA-Tempol
pretreatment groups.
Biochemical markers
The changes in the level of malondialdehyde (MDA) and
glutathione (GSH) in HUVEC cells after X-radiation are
Fig. 6 The effect of AA-Tempol on the protein expressions of Bax, Bcl-2, P53 and caspase-3 in HUVEC cells was determine by immunoblotting
assay (a, b, c, d) Semi-quantified data for the level of the proteins are shown in the lower panel (e). Data represent mean ± S.D. (n = 6).
**P < 0.01 vs. 8 Gy group
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caused a dramatic decrease in GSH level and a signifi-
cantly increase in MDA activity compared to the normal
control group (P < 0.01). Pretreatment with AA-Tempol
can decrease MDA activities (P < 0.01) and increase the
GSH level (P < 0.05) in HUVEC cells significantly com-
pared to the 8Gy X-radiated cells.
Discussion
The present study was to evaluate the effects of X-
radiation on the antioxidant defence system and the
radioprotection afforded by AA-Temopl. The radiation
energy causes damage to living tissues through a series
of molecular events depending on developing reactive
oxygen species (ROS) which are generated by the action
of radiation on water. The major free radicals formed
upon aqueous radiolysis are hydroxyl radical (⋅OH) and
superoxide radical (O⋅2-) [36]. It has been reported that
ionising radiation at cellular level induces damage in the
biologically important macromolecules such as proteins,
lipids, as well as nucleic acids [37]. Approximately 65%
of the DNA damage is caused by the indirect effect of
these free radicals [38] and trigger the oxidation of bio-
molecules leading to the formation of various secondary
free radicals, which can chemically modify DNA, pro-
teins, and lipids, resulting in further cellular damage
[39]. Therefore, antioxidants potentially provide protec-
tion from radiation.
It was reported that Tempol-treated TK6 human lym-
phoblastoid cells, which were known to undergo apop-
tosis in response to radiation exposure, demonstrated adecrease in cytotoxicity after exposure to a 6-Gy dose of
ionizing radiation [40]. In a related experiment, nitrox-
ides were found to protect against lipid peroxidation
[41]. An early radioprotection study showed that the
administration of Tempol to Chinese hamster cells
exposed in culture to lethal doses of gamma-radiation
resulted in a significant and dose-dependent protective
effect with a protection factor of 2.5 compared to the
untreated cells. Stephen M. Hahn reported two Tempol
derivatives, Tempamine and 3-aminomethyl-PROXYL,
exhibited greater radioprotection than Tempol [42]. A
phase I clinical trial in patients receiving whole brain
radiotherapy suggested that Tempol may be effective at
preventing radiation-induced alopecia with only mild
(grade I and II) toxicity [43].
It is known that GSH plays an important role in the
antioxidation of reactive oxygen species (ROS) and free
radicals [44–46]. It is a potent free radical and reactive
oxygen species scavenger [47]. Irreversible cell damage
supervenes when the cell is no longer able to maintain
its GSH content [48]. In the present study, we found
that X-radiation caused a dramatic decrease in the level
of GSH and an increase in the activity of MDA in
HUVEC cells compared with the normal group (P <
0.01), which showed that X-radiation can damage the
redox balance. It has been reported Tempol can in-
creased cell survival and protected against DNA damage
induced by the mutagen neocarzinostatin (NCS), which
had previously been shown to induce its mutagenic
activity via a GSH-dependent mechanism [49]. We
found that when pretreatment with AA-Tempol, a
Fig. 7 The effect of AA-tempol on the activity of the level of MDA (a) and GSH (b) in HUVEC cells *P < 0.05, **P < 0.01 vs. normal group
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vitiy of MDA and increased the GSH level in HUVEC
cells compared with the control group (without AA-
Tempol pretreatment, P < 0.05). This confirms that
AA-Tempol provids protective effects against X-
radiation damage through mediate the antioxidation
system in vitro.
Induction of apoptosis by ionizing radiation is one of
the mechanisms implicated in radiation-induced cyto-
toxicity. During apoptosis induction, many different
activation cascades eventually lead to caspase-3 cleavage
and subsequent cell death [50]. For instance, our previ-
ous studies have revealed that radiation induced apop-
tosis by the release of mitochondrial cytochrome C,
increasing the activation of caspase-3, and up regulating
the expression of Bax and P53 and down regulating the
expression of Bcl-2 [51]. Proteins in the Bcl-2 protein
family are important in the regulation of cell apoptosis.
Bcl-2 prevents the opening of the mitochondrialmembrane pores and is the most important anti-
apoptotic gene [52], whereas Bax induces the opening
of membrane pores and is a very important pro-
apoptotic gene [53]. Under the oxidative stress, the
transcription factor p53 is activated and stabilized.
Subsequently, p53 up regulates the expression of
genes that facilitate apoptosis, DNA repair or gen-
omic stability [54]. In the present study, the results
showed that X-radiation dramatically increased the
numbers of apoptotic cells and induced a sharp in-
crease in the Bax, caspase-3 and P53 expression levels
and a marked decrease in the Bcl-2 expression level
compared with the normal control group. The cell
apoptotic death in by radiation is associated with the
elevated production of ROS. Supplementation of anti-
oxidants to improve the efficacy of radiotherapy is
today’s proposed strategy [55]. For instance, Samuni
AM found that Tempol could prevent cell death in
lymphoblastoid cells, which undergo apoptosis in
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radiation-induced increase in p53 observed in un-
treated control cells [40]. Our research indicated that
in HUVEC cells, preatrement of AA-Tempol up-
regulated the expression of Bcl-2 and down-regulated
the expressions of Bax, caspase-3 and P53 after X-
radiation exposure. The ability of AA-Tempol to
attenuate cell apoptosis and regulate the expression
levels of Bcl-2, Bax, caspase-3 and P53 may be due to
its antioxidative capacity, which prevents the accumu-
lation of ROS and other toxic materials to prevents
the induction of cell death.
We believe that the mechanism of AA-Tempol to pro-
tect against ionizing radiation may due to its unique
ability to scavenge the ROS. AA-Tempol belongs to nitr-
oxides, are chemical compounds containing the tertiary
amine (R3N
+-O−) functional group that are oxidized to
form relatively stable nitroxide radicals. These com-
pounds are membrane-permeable radical scavengers
which have SOD and catalase activities though an
oxoammonium/nitroxide redox couple [56–58]. Firstly,
nitroxide radical RR’NO⋅ is converted to the oxoammo-
nium cation (RR’NO+) by the oxidation of protonated
form of superoxide (HO2⋅) [59]. Then RR’NO
+ can be
reduced by O2
⋅− back to the nitroxide radical.
RR’NO⋅ +O2
⋅− + 2H+→ [RR’NO+] + H2O2
[RR’NO+] + O2
⋅−→ RR’NO⋅ +O2
In the whole process, the nitroxide acts as a catalyst
and is not consumed in the process of dismutation of O2
⋅
− to H2O2 and oxygen. Furthermore, nitroxides and hy-
droxylamines can inhibit lipid peroxidation by participat-
ing in redox reactions at every step [60]. Additionally,
nitroxides were shown to confer catalase-like behavior
to heme proteins and to detoxify H2O2 [61] and to par-
ticipate in radical-radical recombination reactions, which
can limit the levels of free radicals and protect cells [62].
In conclusion, the protective effect of AA-Tempol for
the antioxidant defenses in HUVEC cells was investigated.
The results indicated that AA-Tempol increased the level
of GSH and decreasing the level of MDA which acted as
antioxidants by scanvenging ROS. The present data also
showed that pretreatment with AA-Tempol can attenu-
ated X-radition induced cell apoptosis by regulating the
expression levels of Bcl-2, Bax, caspase-3 and P53. These
observations indicate that AA-Tempol may be a potential
therapeutic agent against the radiation damage.
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